Lung Cancer

LEARNING OBJECTIVES

  • Describe the 4 main types of lung cancer: etiology, pathology, staging, treatment and prognosis.

  • Distinguish small cell carcinoma from non-small cell carcinoma.

  • Outline the evidence linking smoking and lung cancer.


Lung Cancer: Aetiology

Highest number of cancer related deaths worldwide.

Lung cancer Risk factors

Age

Ionizing Radiation

Smoking

  • 86% - Tobacco smoking

  • 83% - Active smoking

  • 3% - Environmental tobacco smoke exposure

Occupational exposures e.g asbestos, silica, diesel engine exhaust.

Air pollution

Family History

Symptoms

  • Coughing

  • Weight loss

  • Shortness of breath

  • Chest pain

  • Hemoptysis - coughing up blood, or sputum that is streaked with blood

  • Fever

  • Weakness

  • Lethargy

  • Rarely: difficulty swallowing or wheezing.

Paraneoplastic Syndromes

  • Up to 12% of patients.

  • Most endocrine are related to SCLC (small cell lung cancer).

  • Cushings syndrome with facial edema and cachexia; hypokalemic alkalosis.

  • Inappropriate ADH secretion - low Na resulting from high urine osmolarity and low serum osmolarity - causes irritability, confusion, weakness and seizure in extreme cases.

  • Parathormone-like effect - hypercalcemia, lethargy, polyuria, polydipsia, constipation, abdominal pain.

  • Gonadotropin effects - gynecomastia, testicular atrophy.

Lung Cancer: Types

Small cell Lung Cancer (SCLC)

  • Also known as oat cell carcinoma.

  • Accounts for 80% of all lung cancer.

  • More prevalent in male.

  • Associated with cigarette smoking.

  • Usually accompanied by a paraneoplastic syndrome (myasthenia of Eaton-Lambert syndrome, ectopic coricotropin production, diabetes inspidus).

  • More sensitive to chemotherapy.

  • Poorest survival rate (5 years).

Non-Small Cell Lung Cancer (NSCLC)

Has three main subtypes: squamous cell carcinoma, adenocarcinoma and large cell carcinoma.

  • Squamous cell carcinoma accounts for 30% of all lung cancers;

    • has been associated with smoking and exposure to chemical carcinogens.

    • Starts in the bronchi of the lungs

  • Adenocarcinoma accounts for 30% of invasive lung cancers

    • Has a peripheral location and early lymphatic spread.

    • Most common type of NSCLC especially in non-smokers.

  • Large cell carcinoma accounts for 10% of all lung cancers

    • May show features of squamous or glandular differentiation or both.

    • Tends to grow and spread more quickly than adenocarcinoma and squamous cell carcinoma.

    • Has the poorest 5-year survival rate of all NSCLC.

Lung Cancer: Diagnosis

CHEST X-RAY

  • Solitary pulmonary nodule or mass.

  • Up to 80% of solitary pulmonary nodules (<4cm diameter) in the over 50 age group are cancer.

  • Chest X-Ray may also be used to evaluate the size of the tumor and possible involvement of lymph nodes in the chest.

CT SCAN

  • Particularly useful in identification of lymph node involvement.

  • The NLST (US National Lung Screening Trial) showed a 20% reduction in lung cancer mortality in high-risk participants (smoking history of ≥30 pack-years) aged 55 to 74 years who were randomly assigned to screening with low-dose computed tomography (LDCT) versus those assigned to chest radiography.


    Screening test for early detection of lung carcinoma

  • Early CDT-Lung is a blood test enabling the early detection of lung cancer.

  • The test is currently in clinical use and has already shown that within high-risk populations that cancers can be detected early whilst they are still treatable with the potential for increased patient survival and indeed in some cases cure.

BIOPSY

  • Lung biopsy usually performed when clinical symptoms or findings on a chest x-ray or CT scan suggest lung cancer.

  • Biopsy sample → pathologist for confirmation → tumor staging

  • Information will guide treatment for the cancer and determine the disease prognosis.

Complications

30% presenting with symptoms of metastatic disease e.g bone fracture, CNS symptoms, jaundice (liver).

  • Local spread to nodes characterized by clinical syndromes

    • SVC syndrome - compression from paratrachial nodes.

    • Horners syndrome - cervical sympathetic chain.

Prognosis

  • Most have metastised to distant sites (70%) on presentation (brain, liver, bone, adrenal).

  • 25% have regional lymph node involvement on diagnosis.

  • Most are inoperable (75% NSCLC, age is a factor)>

  • 1 year survival rate = 30%

  • 5 year survival rate = 9%

  • 5 year survival for localized lung lesion 45%

Smoking and Lung Cancer

  • Smoking increases lung cancer risk by 20-30 times compared to non-smokers.

  • Biological mechanisms: presence of carcinogens + DNA damage and mutation.

  • Dose-response relationship

  • Pathological evidence.